Tamer I. Khayal Sells 2,958 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

TransMedics Group Stock Performance

TransMedics Group stock traded down $1.65 during mid-day trading on Monday, hitting $148.45. 1,121,093 shares of the company’s stock traded hands, compared to its average volume of 760,775. The firm has a 50 day moving average price of $144.02 and a 200 day moving average price of $111.51. The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18. The company has a market cap of $4.89 billion, a PE ratio of -441.47 and a beta of 1.99. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $171.98.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a return on equity of 17.37% and a net margin of 0.84%. The firm’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same period last year, the firm earned ($0.03) EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Institutional Trading of TransMedics Group

A number of institutional investors have recently bought and sold shares of the company. Pitcairn Co. lifted its position in shares of TransMedics Group by 1.5% in the first quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock worth $398,000 after buying an additional 78 shares during the last quarter. Signaturefd LLC increased its stake in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the period. Arizona State Retirement System increased its stake in TransMedics Group by 2.1% during the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after acquiring an additional 186 shares during the period. First Horizon Advisors Inc. increased its stake in TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after acquiring an additional 222 shares during the period. Finally, International Assets Investment Management LLC bought a new stake in shares of TransMedics Group in the 2nd quarter valued at approximately $47,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the topic of a number of analyst reports. Stephens lifted their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday. Piper Sandler boosted their price target on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday. Oppenheimer upped their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday. Cantor Fitzgerald initiated coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target for the company. Finally, TD Cowen upped their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $166.88.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.